Danske: Genmab partner might accelerate launch
Fresh data for a rival drug might spur Genmab’s Big Pharma partner Janssen to accelerate plans for the cancer candidate daratumumab.
BY STEFAN SINGH KAILAY
The already great momentum for Genmab-developed cancer drug daratumumab might, perhaps rather paradoxically, be reinforced by solid data from a rival drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab is now worth more than Lundbeck
For abonnenter
Increased belief in Genmab’s potential blockbuster
For abonnenter
